Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors

被引:36
作者
Yoon, Jee Hee [1 ]
Hong, A. Ram [1 ]
Kim, Hee Kyung [1 ]
Kang, Ho-Cheol [1 ]
机构
[1] Chonnam Natl Univ, Dept Internal Med, Med Sch, 160 Baekseo Ro, Gwangju 61469, South Korea
关键词
Programmed cell death 1 receptor; Immune checkpoint inhibitors; Hypothyroidism; Adverse effects; CHECKPOINT INHIBITORS; NIVOLUMAB; BLOCKADE; DEVELOP;
D O I
10.3803/EnM.2020.906
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Thyroid immune-related adverse events (IRAEs) have been reported in patients treated with programmed cell death protein-1 (PD-1) and programmed cell death protein-ligand 1 (PD-L1) inhibitors. We investigated the incidence and clinical course of PD-1/PD-L1 inhibitor-induced thyroid IRAEs, and identified predictable clinical risk factors of thyroid IRAEs, in particular, overt hypothyroidism (OH). Methods: We retrospectively reviewed the medical records of 325 cancer patients receiving PD-1/PD-L1 inhibitor in a tertiary referral center. Results: A total of 50.5% (164/325) of patients experienced at least one abnormal thyroid function following PD-1/PD-L1 inhibitor. Eighty-four patients (51.2%) of them recovered to normal thyroid function during follow-up. In overall population, 25 patients (7.7%) required thyroid hormone replacement therapy due to PD-1/PD-L1 inhibitor-induced OH. Patients who progressed to OH showed significantly higher baseline thyroid stimulating hormone level and longer duration of PD-1/PD-L1 inhibitor therapy than those without thyroid dysfunction or OH (both P< 0.001). Median time interval to the development of OH was 3 months after the therapy. OH was significantly associated with positive anti-thyroid peroxidase antibody at baseline and anti-thyroglobulin antibody during the therapy than those without thyroid dysfunction or OH (P=0.015 and P= 0.005, respectively). We observed no patients with OH who were able to stop levothyroxine replacement after the cessation of PD-1/PD-L1 inhibitor therapy. Conclusion: PD-1/PD-L1 inhibitor-induced thyroid dysfunctions are considerably reversible; however, OH is irreversible requiring levothyroxine replacement even after stopping the therapy. Positive thyroid autoantibodies may predict the progression to OH.
引用
收藏
页码:413 / 423
页数:11
相关论文
共 29 条
[1]   SnapShot: Immune Checkpoint Inhibitors [J].
Abril-Rodriguez, Gabriel ;
Ribas, Antoni .
CANCER CELL, 2017, 31 (06)
[2]   THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW [J].
Al Mushref, Mazen ;
Guido, Paul A. ;
Collichio, Frances A. ;
Moore, Dominic T. ;
Clemmons, David R. .
ENDOCRINE PRACTICE, 2020, 26 (01) :36-42
[3]   Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis [J].
Barroso-Sousa, Romualdo ;
Barry, William T. ;
Garrido-Castro, Ana C. ;
Hodi, F. Stephen ;
Min, Le ;
Krop, Ian E. ;
Tolaney, Sara M. .
JAMA ONCOLOGY, 2018, 4 (02) :173-182
[4]   Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients [J].
Basak, Edwin A. ;
van der Meer, Jan W. M. ;
Hurkmans, Daan P. ;
Schreurs, Marco W. J. ;
Oomen-de Hoop, Esther ;
van der Veldt, Astrid A. M. ;
Bins, Sander ;
Joosse, Arjen ;
Koolen, Stijn L. W. ;
Debets, Reno ;
Peeters, Robin P. ;
Aerts, Joachim G. J., V ;
Mathijssen, Ron H. J. ;
Medici, Marco .
THYROID, 2020, 30 (07) :966-973
[5]   Graves' Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature [J].
Brancatella, Alessandro ;
Viola, Nicola ;
Brogioni, Sandra ;
Montanelli, Lucia ;
Sardella, Chiara ;
Vitti, Paolo ;
Marcocci, Claudio ;
Lupi, Isabella ;
Latrofa, Francesco .
EUROPEAN THYROID JOURNAL, 2019, 8 (04) :192-195
[6]   VOLUMETRIC-ANALYSIS OF THYROID LOBES BY REAL-TIME ULTRASOUND [J].
BRUNN, J ;
BLOCK, U ;
RUF, G ;
BOS, I ;
KUNZE, WP ;
SCRIBA, PC .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1981, 106 (41) :1338-1340
[7]   Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints [J].
Chang, Lee-Shing ;
Barroso-Sousa, Romualdo ;
Tolaney, Sara M. ;
Hodi, F. Stephen ;
Kaiser, Ursula B. ;
Min, Le .
ENDOCRINE REVIEWS, 2019, 40 (01) :17-65
[8]  
Choi J, 2020, IMMUNE NETW, V20
[9]   Immune checkpoint inhibitors: recent progress and potential biomarkers [J].
Darvin, Pramod ;
Toor, Salman M. ;
Nair, Varun Sasidharan ;
Elkord, Eyad .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 :1-11
[10]   Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors [J].
de Moel, Emma C. ;
Rozeman, Elisa A. ;
Kapiteijn, Ellen H. ;
Verdegaal, Els M. E. ;
Grummels, Annette ;
Bakker, Jaap A. ;
Huizinga, Tom W. J. ;
Haanen, John B. ;
Toes, Rene E. M. ;
van der Woude, Diane .
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) :6-11